Lymph Node News and Research

RSS

Lymph is clear or white fluid that travels through vessels, moves within tissues and work to keep all the parts of the body clean. After passing through the channels of the lymphatic system they drain into the lymph nodes. The lymph nodes act as filters along the lymphatic system. These nodes trap germs like bacteria, viruses, toxins as well as cancer cells and ensure that these are removed from the body.

Drop in U.S. colorectal cancer deaths

The American Society for Gastrointestinal Endoscopy (ASGE) lauds the recent news of the decline in U.S. colorectal cancer death and incidence rates. The report, released this week, shows that from 1975 to 2000, incidence rates dropped 22 percent and death rates dropped 26 percent.

10 Dec 2009

Neoprobe completes Phase 3 Lymphoseek clinical trial on breast cancer patients

Neoprobe Corporation (OTCBB: NEOP), a diversified developer of innovative oncology surgical and diagnostic products, has completed a Phase 3 clinical trial of Lymphoseek® (NEO3-05) with positive results.

9 Dec 2009

Updated clinical data of Calistoga Pharmaceuticals’ delta selective PI3K inhibitor presented

Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, today announced updated clinical data on CAL-101, the Company’s oral, delta selective PI3K inhibitor, presented during two oral presentations at the 51st American Society of Hematology Annual Meeting in New Orleans.

8 Dec 2009

Gloucester Pharmaceuticals to be acquired by Celgene

Celgene Corporation and Gloucester Pharmaceuticals Inc., a privately held pharmaceutical company, announced a definitive merger agreement under which Celgene Corporation will acquire Gloucester Pharmaceuticals. Celgene says the acquisition will continue to advance its leadership position in the development of disease-altering therapies through innovative approaches for patients with rare and debilitating blood cancers.

7 Dec 2009

Positive data from Gloucester Pharmaceuticals' ISTODAX study presented at the ASH meeting

Gloucester Pharmaceuticals announced today the presentation of positive data from an analysis of ISTODAX® (romidepsin) in a subset of patients from Gloucester’s registration study in cutaneous T-cell lymphoma (CTCL) at the 51st American Society of Hematology (ASH) Annual Meeting being held in New Orleans, LA.

7 Dec 2009

Genomic Health to present its Oncotype DX multi-gene expression test studies at the 32nd SABCS

Genomic Health, Inc. today announced that the company will present results from five studies at the 32nd Annual San Antonio Breast Cancer Symposium (SABCS), taking place December 9-13, 2009, at the Henry B. Gonzalez Convention Center.

5 Dec 2009

Bioactive sponge to eliminate normally fatal tumors

InCytu Incorporated, a therapeutic device engineering company, announced the details of its Cellarium™ Cancer Vaccine program. Cellarium™ is a small bioactive sponge which regulates dendritic cells and T-cells to eliminate normally fatal tumors in a preclinical model of late stage melanoma. The details of such a promising new vaccine were published for the first time in Science’s Translational Medicine Journal.

2 Dec 2009

Research shows link between nervous and immune systems; findings may lead to new treatments for autoimmune disorders

New research in the Journal of Leukocyte Biology shows the link between the nervous and immune systems and how breaking that link might lead to new treatments for a wide range of autoimmune disorders

1 Dec 2009

EMEA grants orphan drug status for LFB Biotechnologies' recombinant anti-CD20 monoclonal antibody

The recombinant anti-CD20 monoclonal antibody produced by LFB Biotechnologies received orphan drug status for the treatment of Chronic Lymphocytic Leukemia (CLL). This approval from the EMEA’s Committee for Orphan Medicinal Products (COMP) was handed down on last October 7th.

25 Nov 2009

Combination therapy improves survival rates of patients with head and neck cancer

Cancer Research UK scientists have found that a combination of chemotherapy and radiotherapy improves survival from advanced head and neck cancer in patients who are not able to have surgery.

23 Nov 2009

New pre-clinical data from Alnylam Pharmaceuticals' ALN-VSP program presented

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today announced new pre-clinical data from its ALN-VSP program presented at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics International conference being held November 15 - 19, 2009 in Boston, Mass.

18 Nov 2009

Researchers identify new way to capture tumor cells in bloodstream; findings can improve early cancer diagnosis

Jin-Woo Kim, a biomedical engineering researcher at the University of Arkansas, is part of a cutting-edge nanotechnology research group that has discovered a way to capture tumor cells in the bloodstream. The work could dramatically improve early cancer diagnosis and prevent deadly metastasis.

18 Nov 2009

Press conference highlights emerging treatments in pancreatic cancer

As part of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Thompson will moderate a press conference on emerging treatments in pancreatic cancer on Tuesday, Nov. 17, 2009, in Room 202 of the Hynes Convention Center in Boston, Mass., from 1:00 p.m. to 2:00 p.m. ET.

18 Nov 2009

Trubion Pharmaceuticals to present data on its TRU-016 product candidate at the ASH meeting

Trubion Pharmaceuticals, Inc. announced today the acceptance of two data presentations on its product candidate, TRU-016, at the 2009 American Society of Hematology (ASH) Annual Meeting Dec. 5-8, 2009 in New Orleans, Louisiana.

12 Nov 2009

New robotic surgical systems from El Camino Hospital

El Camino Hospital, the hospital of Silicon Valley, expands its minimally invasive surgical program to three da Vinci® Si HD Surgical Systems. Physicians performed more than 500 robotic surgeries over the past year and expect the number to increase in 2010 as more physicians undergo training with the enhanced equipment that allows for more minimally invasive procedures.

11 Nov 2009

New technique to identify patients more likely to survive advanced melanoma

Although the chances of surviving advanced melanoma aren't very good with current therapies, some patients can live for years with cancer that has spread beyond the skin to other organs. Now it may be possible to identify which patients are more likely to survive by analyzing the activity of hundreds of genes involved in the immune response and gene proliferation, according to researchers at NYU Langone Medical Center.

10 Nov 2009

FDA approves Istodax for treatment of Cutaneous T-cell Lymphoma

The U.S. Food and Drug Administration has approved Istodax (romidepsin), an injectable medication, for treatment of patients with a rare form of cancer known as Cutaneous T-cell Lymphoma (CTCL).

10 Nov 2009

Study suggests three-week course of radiation therapy effective for breast cancer patients

According to a study presented November 4, 2009, at the 51st Annual Meeting of the American Society for Radiation Oncology (ASTRO), a shortened, more intensive course of radiation given to the whole breast, along with an extra dose of radiation given to the surgical bed of the tumor (concomitant boost), has been shown to result in excellent local control at a median follow up of two years after treatment with no significant side effects.

5 Nov 2009

Short, intensive radiation therapy offers similar results as conventional therapy for early stage-breast cancers

5 Nov 2009

EUSA Pharma's PROSTASCINT effective in guiding targeted prostate cancer treatment

EUSA Pharma announced that PROSTASCINT® (capromab pendetide) fusion imaging was shown to effectively guide prostate cancer therapy targeting and dosing and is a significant predictor of disease free survival, according to data presented on Tuesday, November 3, 2009 at the 51st American Society for Therapeutic Radiology and Oncology (ASTRO) annual meeting in Chicago, Illinois.

4 Nov 2009

Lymph Node News and Research

Further Reading

Drop in U.S. colorectal cancer deaths

Neoprobe completes Phase 3 Lymphoseek clinical trial on breast cancer patients

Updated clinical data of Calistoga Pharmaceuticals’ delta selective PI3K inhibitor presented

Gloucester Pharmaceuticals to be acquired by Celgene

Positive data from Gloucester Pharmaceuticals' ISTODAX study presented at the ASH meeting

Genomic Health to present its Oncotype DX multi-gene expression test studies at the 32nd SABCS

Bioactive sponge to eliminate normally fatal tumors

Research shows link between nervous and immune systems; findings may lead to new treatments for autoimmune disorders

EMEA grants orphan drug status for LFB Biotechnologies' recombinant anti-CD20 monoclonal antibody

Combination therapy improves survival rates of patients with head and neck cancer

New pre-clinical data from Alnylam Pharmaceuticals' ALN-VSP program presented

Researchers identify new way to capture tumor cells in bloodstream; findings can improve early cancer diagnosis

Press conference highlights emerging treatments in pancreatic cancer

Trubion Pharmaceuticals to present data on its TRU-016 product candidate at the ASH meeting

New robotic surgical systems from El Camino Hospital

New technique to identify patients more likely to survive advanced melanoma

FDA approves Istodax for treatment of Cutaneous T-cell Lymphoma

Study suggests three-week course of radiation therapy effective for breast cancer patients

Short, intensive radiation therapy offers similar results as conventional therapy for early stage-breast cancers

EUSA Pharma's PROSTASCINT effective in guiding targeted prostate cancer treatment

Immunology eBook

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

Latest News